Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange Detected- Revision: v3.4.2 has been added. The government funding notice and Revision: v3.4.1 banner have been removed; no study content or eligibility information was changed.SummaryDifference0.3%

- Check21 days agoChange DetectedResults status updated from No Results Posted to Results Submitted, and the page revision shows Revision: v3.4.1. A government-funding status notice about NIH operations is also displayed.SummaryDifference0.3%

- Check28 days agoChange DetectedUI updates include showing a glossary and new metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0) along with the removal of older labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedPage footer revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check64 days agoChange DetectedThe locations section has been expanded to list more trial sites across the US, Canada, Australia, Europe, and Asia, organized by region. This makes it easier for potential participants to find a nearby site and assess eligibility.SummaryDifference1%

- Check85 days agoChange DetectedNon-substantive metadata updates were made: a general note about voluntary publication submissions was added (2025-11-25), the 'Last Update Posted (Estimated)' field was updated (2025-11-20), and an earlier PubMed-based publication note and prior 'Last Update Posted' entry were removed (September 2024).SummaryDifference0.2%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.